TransMedics to Present at the 39th Annual J.P. Morgan Healthcare Conference
TransMedics Group (Nasdaq: TMDX) announced its management will present at the 39th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TransMedics Group (Nasdaq: TMDX) announced its management will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2020, at 5:20 p.m. EST. The company specializes in transforming organ transplant therapy through portable extracorporeal warm perfusion technology.
The presentation will be accessible live and in archive via the Investors section of their website.
Details
News Market Reaction – TMDX
The recorded move for TMDX in the trading session of this news was -0.37%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ANDOVER, Mass., Dec. 24, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that members of the management team will present virtually at the upcoming 39th Annual J.P. Morgan Healthcare Conference. Management is scheduled to present on Wednesday, January 13, 2020 at 5:20 p.m. Eastern Standard Time.
Event: 39th Annual J.P. Morgan Healthcare Conference
Date: Wednesday, January 13, 2020
Time: 5:20 p.m. EST
A live and archived webcast of the presentation will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/.
About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
View original content to download multimedia:http://www.prnewswire.com/news-releases/transmedics-to-present-at-the-39th-annual-jp-morgan-healthcare-conference-301198336.html
SOURCE TransMedics Group, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.